2022-06-13 08:30:00
Last day of trading with the warrants of series TO 3 in Dicot
Today, June 13, 2022, is the last day of trading with the warrants of series TO 3. The subscription period for the warrants of series TO 3 will continue up until June 15, 2022.
Terms for the warrants of series TO 3 in short:
One (1) warrant of series TO 3 entitles the owner to subscribe for one (1) new share in the Company.
Subscription price: 0,29 SEK per new issued share
Volume: 38068461 warrants of series TO 3. If fully exercised, 38068461 new shares are issued, and the Company will receive at most approximately 11 MSEK before transaction costs
Subscription period: June 1, 2022 - June 15, 2022
Trading with warrants of series TO 3: Warrants of series TO 3 can be traded at Spotlight Stock Market under the ticker ``DICOT TO 3`` with ISIN-code SE0016844450. Last day of trading with warrants of series TO 3 is June 13, 2022.
Note that the warrants that are not used to subscribe for new shares, or are sold in the market before June 13, 2022, or are used for subscription at latest June 15, 2022, will expire and thus lose their value. To ensure that the warrant owner's warrants of series TO 3 don't expire without value the owner has to actively subscribe for shares or sell their warrants in the market.
Complete terms for the warrants of series TO 3 was included in the prospectus regarding the rights issue of units released on September 8, 2021. An independent document with complete terms for the warrants of series TO 3 as well as the prospectus is available at the above-mentioned web address.
How to use the warrants:
Trustee registered warrants (Custody account)
Subscription and payment with the use of warrants of series TO 3 shall be made in accordance with instructions from each trustee. If you have further questions regarding subscription and payment please contact your trustee for additional information in good time before June 15, 2022, as different trustees may have different processing times.
Directly registered warrants (Securities account)
Directly registered holders (holdings on a VP account) of warrants of series TO 3 must notify redemption of warrants by filling in and sending a notification form for the exercise of warrants, so that it is received by the issuing institution Hagberg & Aneborn Fondkommission AB no later than 15.00 on 15 June 2022.
No accounts for issuing nor any instructions regarding payments will be sent out. Subscriptions will be made through simultaneous payment in accordance with the instructions on the application form. The warrants will then be replaced by interim shares (IS) awaiting registration at the Swedish Companies Registration Office.
The subscription form is available at the Companys homepage, www.dicot.se, and on Hagberg & Aneborn Fondkommissions homepage www.hagberganeborn.se
Advisers
Stockholm Corporate Finance AB is the financial adviser and Advokatfirman Lindahl KB is legal adviser regarding the warrants of series TO 3. Hagberg & Aneborn Fondkommission AB acts as issuing agent regarding the warrants of series TO 3.
Uppsala, June 13, 2022
For questions regarding the warrants, please contact:
Hagberg & Aneborn Fondkommission AB
Phone: + 46 (0) 840 89 33 50
Email: [email protected]
For additional questions regarding the warrants, please contact:
Elin Trampe, CEO
Phone: +46 (0) 739 80 14 08
Email: [email protected]
About Dicot AB
Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.
Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se
Nerladdningsbara filer
Dicot uppvisar goda resultat i ny effektstudie
2022-06-29 14:30
Pressmeddelande: Uppsala, 29 juni 2022. Dicot AB utvecklar ett nytt potensläkemedel med målsättningen att bli förstahandsvalet på marknaden. Bolaget meddelar idag att den nyutvecklade orala formuleringen uppvisar goda resultat i en nyligen genomförd effektstudie.
Dicot demonstrates good results in new efficacy study
2022-06-29 14:30
Press release: Uppsala, June 29, 2022. Dicot AB is developing a new potency drug aiming at becoming the first choice of treatment. The company announces today that the newly developed oral formulation demonstrates good results in a recently conducted efficacy study.
Dicot tillförs 10 MSEK genom utnyttjande av teckningsoptioner av serie TO 3 till 90% teckningsgrad
2022-06-17 18:35
Pressmeddelande: Uppsala, 17 juni 2022.
Dicot AB (publ) ("Dicot" eller "Bolaget") meddelar utfallet från utnyttjandet av teckningsoptioner av serie TO 3. Innehavare av teckningsoptioner utnyttjade 34 202 814 teckningsoptioner, motsvarande cirka 90 procent av antalet utestående teckningsoptioner, för teckning av 34 202 814 aktier till teckningskursen 0,29 SEK per aktie. Genom utnyttjandet av teckningsoptionerna tillförs Dicot cirka 10 MSEK före emissionskostnader.
Dicot AB receives approximately 10 MSEK through the warrants of series TO 3 with a 90% subscription rate
2022-06-17 18:35
Press release: Uppsala, June 17, 2022.
Dicot AB (publ) ("Dicot" or the "Company") announces the outcome regarding exercising of warrants of series TO 3. Holders of warrants exercised 34,202,814 warrants, corresponding to approximately 90 percent of the number of outstanding warrants, for subscription of 34,202,814 shares at a subscription price of SEK 0.29 per share. Through the exercise of the warrants, Dicot will receive approximately SEK 10 million before issue costs.
Medlemmar i Dicots styrelse och ledning stärker aktieinnehavet
2022-06-13 15:43
Pressmeddelande: Uppsala, 13 juni 2022. Bolaget meddelar idag att medlemmar i Dicots styrelse och ledning ökar sitt aktieinnehav i bolaget.
Members of Dicot's board and management strengthen their shareholding
2022-06-13 15:43
Press release: Uppsala, June 13, 2022. The company announces that members in the board and management are increasing their shareholding in the company.
Sista dag för handel med teckningsoptioner av serie TO 3 i Dicot
2022-06-13 08:30
Den 13 juni 2022 är den sista dagen för handel med teckningsoptioner av serie TO 3 i Dicot AB (publ) ("Dicot" eller "Bolaget"). Utnyttjandeperioden för teckningsoptionerna av serie TO 3 pågår till och med den 15 juni 2022.
Last day of trading with the warrants of series TO 3 in Dicot
2022-06-13 08:30
Today, June 13, 2022, is the last day of trading with the warrants of series TO 3. The subscription period for the warrants of series TO 3 will continue up until June 15, 2022.
Dicot går vidare med ny patentansökan
2022-06-10 09:45
Pressmeddelande: Uppsala, 10 juni 2022. Dicot AB utvecklar läkemedelskandidaten LIB-01, ett potensläkemedel för att bättre behandla erektil dysfunktion och tidig utlösning. Bolaget meddelar att man nu går vidare med en ny patentansökan för att förlänga patentskyddet runt bolagets läkemedelskandidat till minst 2042.
Dicot moves forward with a new patent application
2022-06-10 09:45
Press release: Uppsala, June 10, 2022. Dicot AB is developing the drug candidate LIB-01, a potency drug to better treat erectile dysfunction and premature ejaculation. The company announces that it is now moving forward with a new patent application in order to extend the patent protection around the company's drug candidate until at least 2042.
Dicot presenterar på Småbolagsdagarna måndag 13 juni
2022-06-09 10:51
Uppsala, 9 juni 2022. Möt Dicots vd Elin Trampe på Småbolagsdagarna måndag 13 juni när hon presenterar bolagets utveckling av ett nytt potensläkemedel och de senaste framstegen. Hon kommer bland annat berätta om ett nystartat projekt med Uppsala universitet samt lyfta frågan om tystnadskulturen bland män med erektionsproblem.
Dicot presents at Småbolagsdagarna, Monday June 13
2022-06-09 10:51
Uppsala, June 9, 2022. Meet Dicot's CEO Elin Trampe at Småbolagsdagarna on Monday June 13 when she presents the company's development of a new potency drug and the latest advances. Among other things, she will talk about a newly started project with Uppsala University and raise the issue of the culture of silence among men with erectile dysfunction.
Utnyttjandeperioden för teckningsoptioner av serie TO 3 i Dicot inleds idag
2022-06-01 08:30
Idag, den 1 juni 2022, inleds utnyttjandeperioden för de teckningsoptioner av serie TO 3 som emitterades i samband med Dicot AB (publ) ("Dicot" eller "Bolaget") emission av units under det fjärde kvartalet 2021. Utnyttjandeperioden pågår till och med den 15 juni 2022.
The subscription period for warrants of series TO 3 in Dicot begins today
2022-06-01 08:30
Today on June 1, 2022, the subscription period for the warrants of series TO 3 issued in connection with the rights issue of units in Dicot AB (publ) during the fourth quarter of 2021. The subscription period lasts until June 15, 2022.
Dicot AB går in i forskningssamarbete med Uppsala universitet och W. Szafer Institute of Botany
2022-05-31 13:00
Uppsala, 31 maj 2022. Dicot AB utvecklar läkemedelskandidaten LIB-01, ett potensläkemedel för att bättre behandla erektil dysfunktion och tidig utlösning. Dicot meddelar idag att bolaget har inlett ett forskningssamarbete med Uppsala universitet och W. Szafer Institute of Botany vid Polska Vetenskapsakademin för att undersöka en ny teknik för framtagning av startmaterial för tillverkning av läkemedelssubstansen.
Dicot AB enters research collaboration with Uppsala University and the W. Szafer Institute of Botany
2022-05-31 13:00
Uppsala, May 31, 2022. Dicot AB is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. Dicot announces today that the company has entered a research collaboration with Uppsala University and the W. Szafer Institute of Botany of the Polish Academy of Sciences (PAS) to investigate a new technology to make starting material for production of the drug substance.
Teckningskursen för utnyttjandet av teckningsoptioner av serie TO 3 i Dicot har fastställts till 0,29 SEK per aktie
2022-05-29 21:00
Pressmeddelande: Uppsala, 29 maj 2022.
Dicot AB (publ) ("Dicot" eller "Bolaget") genomförde under det fjärde kvartalet 2021 en företrädesemission av s.k. units vari en (1) unit bestod av tre (3) nyemitterade aktier och tre (3) vederlagsfria teckningsoptioner av serie TO 3 (även tidigare benämnd serie 2021/2022). De som tecknade units under teckningsperioden från och med den 12 oktober 2021 till och med den 27 oktober 2021 erhöll därmed tre (3) vidhängande vederlagsfria teckningsoptioner av serie TO 3 per tecknad unit i företrädesemissionen. Varje teckningsoption av serie TO 3 ger rätt att teckna en (1) ny aktie i Bolaget. Teckningskursen för teckningsoptionerna motsvarar 70 procent av den volymvägda genomsnittskursen i Bolagets aktie under perioden från och med den 16 maj 2022 till och med 27 maj 2022, dock inte lägre än aktiens kvotvärde (0,125 SEK) och inte högre än 1,50 SEK per aktie. Den genomsnittliga betalkursen uppgick under mätperioden till cirka 0,41 SEK och således är lösenpriset fastställt till 0,29 SEK per aktie.
The subscription price for the exercise of warrants of series TO 3 in Dicot AB has been set to 0.29 SEK per share
2022-05-29 21:00
Press release: Uppsala, May 29, 2022.
During the fourth quarter of 2021, Dicot AB (publ) (``Dicot`` or ``the Company``) conducted a rights issue of units, with one (1) unit consisting of three (3) new issued shares and three (3) free-of-charge warrants of series TO 3 (previously also named series 2021/2022). Those who subscribed for units during the subscription period between October 12, 2021, and October 27, 2021, therefore obtained three (3) additional warrants of series TO 3 per unit subscribed. Each warrant of series TO 3 entitles the holder to subscribe for one (1) new share in Dicot. The subscription price for subscription of shares using warrants will correspond to 70 percent of the average volume-weighted price of the Company's share according to Spotlight Stock market's official list during the period from May 16, 2022, up to and including May 27, 2022. However, the subscription price shall not be higher than 1.50 SEK or lower than 0.125 SEK (corresponding quota value of the Company's share). The average volume-weighted price of the Company's share during the measurement period amounted to approximately 0.41 SEK, hence, the subscription price has been set to 0.29 SEK per share.
Kommuniké från årsstämma i Dicot AB
2022-05-24 11:15
Dicot AB (publ) ("Bolaget") höll idag den 24 maj 2022 årsstämma i Uppsala varvid nedan beslut fattades.
Dicot AB
Webbplats:
www.dicot.se/
Kortnamn: DICOT
Marknadsplats: Spotlight Stock Market
Senaste rapporten:
Delårsrapport Q1 2022
Interim report Q1 2022
Nästa evenemang:
2022-08-25 Delårsrapport Q2 2022
Kurs
Kurs:
Marknadsvärde:
